Under the terms of the collaboration, Iktos will apply its generative AI and AI-orchestrated robotics platform to design, ...

| Servier is committing to rare neurology for the long term, using focused science and strategic collaborations to bring new ...

Independent French pharma major Servier today announced the creation of Servier Ventures, a fully owned corporate venture ...

The alliance with Paris, France-based Iktos could be worth more than €1 billion in upfront, research funding, and milestone ...

Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

Right on the heels of its IPO, Insilico Medicine is starting the year with an oncology discovery and development pact with French pharma Servier.  | Right on the heels of its IPO, Insilico Medicine is ...

"Insilico and Servier announce $888m oncology research agreement" was originally created and published by Pharmaceutical ...

Servier has expanded its IDH drug armamentarium with the FDA approval for an IDH1/2 dual inhibitor. The approval represents the first major treatment advance in low-grade brain cancer in more than two ...

Servier, a global independent pharmaceutical group, is undertaking one of its most ambitious transformations to date, ...

China-based Insilico Medicine, an AI-driven drug discovery firm, announced a multi-year research and development (R&D) ...

Two years ago, with a favorable ruling and a slap-on-the-wrist fine, Servier hoped its decades-long litigation surrounding weight-loss pill Mediator was finally over. But an appeal from prosecutors ...